逆转录病毒和机会感染大会（CROI） 2015 会议总结来自TAG

marine0425030

CROI 2015 会议总结

近日在华盛顿州西雅图召开的逆转录病毒与机会性感染(CROI)2015年会顺利结束。TAG小组对这次会议做了些小结。他们认为这次会议最令人激动的新闻是关于两个暴露前预防的研究：PROUDand IPERGAY.

在艾滋病疫苗研究方面并没有太大的突破，但也有不少非常有趣的研究。有兴趣的可以查阅主页和视频。

TAG小组也列出了些他们觉得比较有趣的研究

A Path to an HIV Vaccine

Galit Alter, Ragon Institute of MIT,MGH and Harvard, Cambridge, MA, United States

- 她对艾滋病疫苗的发展做了一个总结和展望。

Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-InfectedART-Suppressed Monkeys

James B. Whitney, BethIsrael Deaconess Medical Center, Harvard Medical School, Boston, MA, UnitedStates

该研究利用TLR7的激动剂来激活潜伏SIV病毒的再复制，以此为靶点来清除病毒库。

Broadly Neutralizing Antibodies for HIV-1 Eradication Strategies

Dan H. Barouch, BethIsrael Deaconess Medical Center, Harvard Medical School, Boston, MA, UnitedStates

-该研究主要是想将抗体和ART合并使用来减少病毒的潜伏库。

Post-Treatment Controllers Have Particular NK Cells With High Anti-HIVCapacity: VISCONTI Study

Daniel Scott-Algara, InstitutPasteur, Paris, France

该项VISCONTI研究表明天然杀伤性细胞(NK)制病毒复制起到一定的作用。该研究比较了天然杀伤性细胞(NK)功能，但是他们并未对炎症和免疫激活进行分析，所以NK时候真正有效还有待数据证明。

Durable Control of Viral Rebound in Humanized Mice by ABX464 TargetingRev Functions

Jamal Tazi, University ofMontpellier, Montpellier, France

该小组研究了针对Rev蛋白的抑制物，人源化小鼠模型实验证实该分子可以降低病毒载量。

In vivo effects of Panobinostat and Romidepsin on HIV-1-specific CD8 TCell Immunity. Rikke Olesen et al. Abstract Number: 369.

临床试验分析数据表明组蛋白去乙酰酶(HDAC)抑制剂在体内并不能有效抑制CD8 T细胞的反应，这与前几天体外实验有些相互冲突。

- An analysis of samples fromtwo clinical trials indicating that HDAC inhibitors do not significantlysuppress HIV-specific CD8 T cell responses in vivo, in contrast to the resultsof an in vitro study published last year.

Selectively Eliminating HIV Latently Infected Cells Without Viral Reactivation.Grant Campbell et al. Abstract Number: 387

- Laboratory study reportinglatently infected cells may be distinguished from uninfected cells due toexpression of X-linked inhibitor of apoptosis protein (XIAP), and that this mayallow them to be selectively eliminated with an XIAP antagonist drug, GDC-0152.Sounds potentially exciting, but will need to be confirmed using primarylatently infected CD4 T cells sampled from HIV-positive individuals on ART.

Targeting HIV-1 Latency With a Potent Tat Inhibitor. GuillaumeMousseau et al. Abstract Number: 413

- In the early 1990s clinicaltrials were conducted of a Tat inhibitor developed by Hoffman-LaRoche but itfailed to show efficacy. This study describes a new candidate and suggests theidea should be revisited in the context of targeting HIV latency.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treatedduring Acute HIV Infection. Cynthia L. Gay et al. AbstractNumber: 344

- Small trial of a therapeuticHIV vaccine approach in acute HIV infection. Although HIV-specific immuneresponses were induced, this did not lead to sustained control of viral loadafter ART interruption in five out of the six participants, but one individualremains off ART after 268 days. The researchers plan to study AGS-004 incombination with a latency-reversing agent.

Measuring HIV Latency Over Time: Reservoir Stability and Assessing Interventions.Nancie M. Archin et al. Abstract Number: 406

- Anassessment of the reproducibility of the quantitative viral outgrowth assay(QVOA) over time. Changes of >2.5 fold were fairly common, whereas changes>6 fold were rare, lead to the suggestion that the latter should be used asa threshold in evaluations of reservoir-depleting interventions.

总之，该会议的大部分视频都能在其主页webcast的地方找到。

rentianyixu

原来是视频啊，不错，强顶。。。。

rojjer

一手资料，感谢分享。